GB201506423D0 - Gamma delta T cells and uses thereof - Google Patents

Gamma delta T cells and uses thereof

Info

Publication number
GB201506423D0
GB201506423D0 GBGB1506423.1A GB201506423A GB201506423D0 GB 201506423 D0 GB201506423 D0 GB 201506423D0 GB 201506423 A GB201506423 A GB 201506423A GB 201506423 D0 GB201506423 D0 GB 201506423D0
Authority
GB
United Kingdom
Prior art keywords
cells
gamma delta
delta
gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1506423.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TC Biopharm Ltd
Original Assignee
TC Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53333850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201506423(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by TC Biopharm Ltd filed Critical TC Biopharm Ltd
Priority to GBGB1506423.1A priority Critical patent/GB201506423D0/en
Publication of GB201506423D0 publication Critical patent/GB201506423D0/en
Priority to EA201790010A priority patent/EA201790010A1/ru
Priority to KR1020177003596A priority patent/KR20170045205A/ko
Priority to BR112017000464A priority patent/BR112017000464A2/pt
Priority to SG11201700134PA priority patent/SG11201700134PA/en
Priority to PCT/GB2015/051985 priority patent/WO2016005752A1/en
Priority to CN201580037383.2A priority patent/CN107075480A/zh
Priority to CA2954546A priority patent/CA2954546A1/en
Priority to US15/325,012 priority patent/US20170196910A1/en
Priority to EP15745544.5A priority patent/EP3167050A1/en
Priority to AU2015287456A priority patent/AU2015287456A1/en
Priority to JP2017521620A priority patent/JP2017524031A/ja
Priority to CN201680034862.3A priority patent/CN107810267B/zh
Priority to HK18110017.8A priority patent/HK1250741B/en
Priority to US15/566,324 priority patent/US10881688B2/en
Priority to AU2016250211A priority patent/AU2016250211B2/en
Priority to PCT/GB2016/051050 priority patent/WO2016166544A1/en
Priority to SG11201708401WA priority patent/SG11201708401WA/en
Priority to KR1020177032986A priority patent/KR20180012754A/ko
Priority to CN202210369545.4A priority patent/CN114717194A/zh
Priority to JP2017554035A priority patent/JP6995624B2/ja
Priority to CA2982523A priority patent/CA2982523A1/en
Priority to EP16721208.3A priority patent/EP3283620B1/en
Priority to ES16721208T priority patent/ES2993441T3/es
Priority to EA201792041A priority patent/EA201792041A1/ru
Priority to BR112017022249A priority patent/BR112017022249A2/pt
Priority to IL24997017A priority patent/IL249970B/en
Priority to ZA2017/06922A priority patent/ZA201706922B/en
Priority to IL255011A priority patent/IL255011B/en
Priority to US16/859,954 priority patent/US20210030794A1/en
Priority to JP2020115432A priority patent/JP2020172522A/ja
Priority to US16/953,068 priority patent/US20210252055A1/en
Priority to JP2021203173A priority patent/JP2022046549A/ja
Priority to AU2022203664A priority patent/AU2022203664A1/en
Priority to JP2023088259A priority patent/JP2023123437A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1506423.1A 2014-07-09 2015-04-15 Gamma delta T cells and uses thereof Ceased GB201506423D0 (en)

Priority Applications (35)

Application Number Priority Date Filing Date Title
GBGB1506423.1A GB201506423D0 (en) 2015-04-15 2015-04-15 Gamma delta T cells and uses thereof
JP2017521620A JP2017524031A (ja) 2014-07-09 2015-07-08 ガンマデルタｔ細胞およびその使用
AU2015287456A AU2015287456A1 (en) 2014-07-09 2015-07-08 Gamma delta T cells and uses thereof
BR112017000464A BR112017000464A2 (pt) 2014-07-09 2015-07-08 células gama delta t e uso das mesmas
KR1020177003596A KR20170045205A (ko) 2014-07-09 2015-07-08 감마 델타 t 세포 및 이의 용도
EA201790010A EA201790010A1 (ru) 2014-07-09 2015-07-08 Гамма-дельта t-клетки и их применение
SG11201700134PA SG11201700134PA (en) 2014-07-09 2015-07-08 Gamma delta t cells and uses thereof
PCT/GB2015/051985 WO2016005752A1 (en) 2014-07-09 2015-07-08 Gamma delta t cells and uses thereof
CN201580037383.2A CN107075480A (zh) 2014-07-09 2015-07-08 γδT细胞及其用途
CA2954546A CA2954546A1 (en) 2014-07-09 2015-07-08 Gamma delta t cells and uses thereof
US15/325,012 US20170196910A1 (en) 2014-07-09 2015-07-08 Gamma delta t cells and uses thereof
EP15745544.5A EP3167050A1 (en) 2014-07-09 2015-07-08 Gamma delta t cells and uses thereof
EA201792041A EA201792041A1 (ru) 2015-04-15 2016-04-14 Модифицированные гамма-дельта-t-клетки и их применение
BR112017022249A BR112017022249A2 (pt) 2015-04-15 2016-04-14 células t gama delta modificadas e usos destas
AU2016250211A AU2016250211B2 (en) 2015-04-15 2016-04-14 Modified gamma delta cells and uses thereof
ES16721208T ES2993441T3 (en) 2015-04-15 2016-04-14 Modified gamma delta cells and uses thereof
US15/566,324 US10881688B2 (en) 2015-04-15 2016-04-14 Modified gamma delta T cells and uses thereof
CN201680034862.3A CN107810267B (zh) 2015-04-15 2016-04-14 修饰的γδ细胞及其用途
PCT/GB2016/051050 WO2016166544A1 (en) 2015-04-15 2016-04-14 Modified gamma delta cells and uses thereof
SG11201708401WA SG11201708401WA (en) 2015-04-15 2016-04-14 Modified gamma delta cells and uses thereof
KR1020177032986A KR20180012754A (ko) 2015-04-15 2016-04-14 변형된 감마 델타 t 세포 및 이의 용도
CN202210369545.4A CN114717194A (zh) 2015-04-15 2016-04-14 修饰的γδ细胞及其用途
JP2017554035A JP6995624B2 (ja) 2015-04-15 2016-04-14 修正ガンマデルタｔ細胞およびその使用
CA2982523A CA2982523A1 (en) 2015-04-15 2016-04-14 Modified gamma delta t cells and uses thereof
EP16721208.3A EP3283620B1 (en) 2015-04-15 2016-04-14 Modified gamma delta cells and uses thereof
HK18110017.8A HK1250741B (en) 2015-04-15 2016-04-14 Modified gamma delta cells and uses thereof
IL24997017A IL249970B (en) 2014-07-09 2017-01-08 Gamma delta t cells and uses thereof
ZA2017/06922A ZA201706922B (en) 2015-04-15 2017-10-12 Modified gamma delta cells and uses thereof
IL255011A IL255011B (en) 2015-04-15 2017-10-15 Modified gamma delta cells and their uses
US16/859,954 US20210030794A1 (en) 2014-07-09 2020-04-27 Gamma delta t cells and uses thereof
JP2020115432A JP2020172522A (ja) 2014-07-09 2020-07-03 ガンマデルタｔ細胞およびその使用
US16/953,068 US20210252055A1 (en) 2015-04-15 2020-11-19 Modified gamma delta t cells and uses thereof
JP2021203173A JP2022046549A (ja) 2015-04-15 2021-12-15 修正ガンマデルタｔ細胞およびその使用
AU2022203664A AU2022203664A1 (en) 2015-04-15 2022-05-30 Modified gamma delta cells and uses thereof
JP2023088259A JP2023123437A (ja) 2014-07-09 2023-05-29 ガンマデルタｔ細胞およびその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1506423.1A GB201506423D0 (en) 2015-04-15 2015-04-15 Gamma delta T cells and uses thereof

Publications (1)

Publication Number Publication Date
GB201506423D0 true GB201506423D0 (en) 2015-05-27

Family

ID=53333850

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1506423.1A Ceased GB201506423D0 (en) 2014-07-09 2015-04-15 Gamma delta T cells and uses thereof

Country Status (15)

Country Link
US (2) US10881688B2 (enExample)
EP (1) EP3283620B1 (enExample)
JP (2) JP6995624B2 (enExample)
KR (1) KR20180012754A (enExample)
CN (2) CN114717194A (enExample)
AU (2) AU2016250211B2 (enExample)
BR (1) BR112017022249A2 (enExample)
CA (1) CA2982523A1 (enExample)
EA (1) EA201792041A1 (enExample)
ES (1) ES2993441T3 (enExample)
GB (1) GB201506423D0 (enExample)
IL (1) IL255011B (enExample)
SG (1) SG11201708401WA (enExample)
WO (1) WO2016166544A1 (enExample)
ZA (1) ZA201706922B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
EP4295914A3 (en) 2015-09-03 2024-04-10 The UAB Research Foundation Genetically-engineered drug resistant t cells and methods of using the same
WO2018055191A1 (en) * 2016-09-26 2018-03-29 Tessa Therapeutics Pte. Ltd. T cell expansion method
WO2018107134A1 (en) 2016-12-09 2018-06-14 The Uab Research Foundation Chimeric chlorotoxin receptors
GB201701332D0 (en) * 2017-01-26 2017-03-15 Tc Biopharm Ltd Immune cells with modified metabolism and their use thereof
WO2018147805A1 (en) * 2017-02-08 2018-08-16 Agency For Science, Technology And Research Gamma delta t cells and a method of augmenting the tumoricidal activity of the same
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
CA3063807A1 (en) * 2017-05-18 2018-11-22 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
MX2020000900A (es) * 2017-07-29 2021-01-08 Juno Therapeutics Inc Reactivos para expandir celulas que expresan receptores recombinantes.
GB201715918D0 (en) 2017-09-29 2017-11-15 Tc Biopharm Ltd Modified CAR-T
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
CN109777778B (zh) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 一种基因改造的γδT细胞
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
CN108085341A (zh) * 2017-12-28 2018-05-29 河南省华隆生物技术有限公司 一种msgv重组载体及其制备方法和应用
GB201804701D0 (en) * 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
CN108588023B (zh) * 2018-05-09 2020-02-14 河北森朗生物科技有限公司 一种生产嵌合抗原受体修饰的γδT细胞的方法
CN110577932A (zh) * 2018-06-07 2019-12-17 亘喜生物科技（上海）有限公司 一种脐带血来源的嵌合抗原受体t细胞
CN109234236A (zh) * 2018-09-29 2019-01-18 吉林大学第医院 一种嵌合抗原受体γδT细胞的制备方法
EA202190926A1 (ru) * 2018-10-01 2021-06-25 Эдисет Био, Инк. Композиции и способы в отношении сконструированных и несконструированных t-клеток для лечения гематологических опухолей
KR20210087458A (ko) 2018-10-01 2021-07-12 아디셋 바이오, 인크. 고형 종양 치료를 위한 조작된 및 비-조작된 γδ-T 세포에 관한 조성물 및 방법
MY208861A (en) * 2018-11-05 2025-06-04 Xyphos Biosciences Inc Non-natural nkg2d receptors that do not directly signal the cells to which they are attached
CN109517793B (zh) * 2018-11-30 2022-05-10 广州长峰生物技术有限公司 一种NK细胞和γδT细胞共培养的建立方法
EP4219688A1 (en) * 2018-12-19 2023-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Mucosal-associated invariant t (mait) cells expressing chimeric antigen receptors
CN109762843A (zh) * 2018-12-29 2019-05-17 武汉波睿达生物科技有限公司 一种利用脐血来源的cd3阳性t细胞制备通用car-t细胞的方法
CN109609465A (zh) * 2018-12-29 2019-04-12 武汉波睿达生物科技有限公司 一种利用脐血来源的γδT细胞制备CAR-T细胞的方法及该CAR-T细胞和应用
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
AU2020261886A1 (en) * 2019-04-22 2021-11-18 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
US12480958B2 (en) 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides
BR112022002837A2 (pt) * 2019-08-16 2022-05-10 Gammadelta Therapeutics Ltd Anticorpo anti-vd1 ou fragmento do mesmo, anticorpo multiespecífico isolado ou fragmento do mesmo, anticorpo humano e anticorpo multiespecífico isolado humano ou fragmento do mesmo
US20220290101A1 (en) * 2019-08-16 2022-09-15 GammaDelta Therapeutics Limited Ex vivo gamma delta t cell populations
CN110964698B (zh) * 2019-12-25 2022-05-10 杭州中赢生物医疗科技有限公司 一种人工抗原递呈细胞及其制备方法和应用
EP4090432A4 (en) * 2020-01-15 2024-04-17 The Regents Of The University Of California Compositions and methods for altering gamma delta t cell activity
MX2022010461A (es) * 2020-02-24 2022-12-13 Immatics Us Inc Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas.
WO2021176373A1 (en) * 2020-03-03 2021-09-10 Janssen Biotech, Inc. ꝩδ T CELLS AND USES THEREOF
JP2023527502A (ja) * 2020-03-20 2023-06-29 ガンマデルタ セラピューティクス リミティッド 骨髄性悪性病変の治療のためのｖデルタ１＋ｔ細胞
BR112022023371A2 (pt) 2020-05-22 2022-12-20 Chongqing Prec Biotech Co Ltd Proteína de fusão para reversão do microambiente tumoral, vetor de expressão, célula imune, receptor de antígeno quimérico resistente à imunossupressão tumoral, sequência de ácido nucleico, método para preparar uma célula imune, composição farmacêutica, e, uso da composição farmacêutica
EP4189074A4 (en) * 2020-06-22 2025-01-15 Nanjing Legend Biotech Co., Ltd. GENETICALLY MODIFIED GAMMA DELTA T CELLS FOR IMMUNOTHERAPY
IL299886A (en) 2020-07-17 2023-03-01 Instil Bio Uk Ltd Receptors that provide targeted costimulation for host cell therapy
ES2943063T3 (es) * 2020-08-14 2023-06-08 Gammadelta Therapeutics Ltd Anticuerpos multiespecíficos anti-TCR delta variable 1
CN114591907A (zh) * 2020-12-03 2022-06-07 复旦大学 一种γδT细胞的制备和扩增方法以及应用
CN112481284B (zh) * 2020-12-07 2023-07-25 深圳瑞吉生物科技有限公司 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用
CN114685684A (zh) * 2020-12-31 2022-07-01 博生吉医药科技(苏州)有限公司 MUC1-Tn嵌合抗原受体修饰的Vγ9Vδ2T细胞及其应用
EP4294527A1 (en) * 2021-02-17 2023-12-27 GammaDelta Therapeutics Limited Anti-tcr delta variable 1 antibodies
IL305266A (en) 2021-02-17 2023-10-01 Gammadelta Therapeutics Ltd Multispecific antibodies against variable TCR delta 1
JP2024516118A (ja) * 2021-04-06 2024-04-12 ユニセット バイオテック カンパニー リミテッド ライアビリティ カンパニー γδ Ｔ細胞のウイルス形質導入の安定性を改善する方法及びその応用
CN113156142B (zh) * 2021-04-16 2024-09-27 苏州才博医学科技有限公司 一种针对异体cart细胞特异性抗体的检测方法
EP4322972A4 (en) * 2021-04-16 2025-03-12 Acepodia Biotechnologies Ltd. Novel compositions enriched in gamma delta t cells, methods of preparation, and uses thereof
CA3218215A1 (en) * 2021-05-19 2022-11-24 Biliang HU Bi-specific chimeric antigen receptors and genetically engineered immune cells expressing such
EP4355340A4 (en) 2021-06-16 2025-05-21 Instil Bio, Inc. RECEPTORS FOR TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
WO2023288278A1 (en) 2021-07-16 2023-01-19 Instil Bio (Uk) Limited Chimeric molecules providing targeted costimulation for adoptive cell therapy
CN113667640B (zh) * 2021-08-27 2022-09-02 广州百暨基因科技有限公司 CAR-γδT细胞的制备方法
WO2023069322A1 (en) * 2021-10-20 2023-04-27 University Of Pittsburgh – Of The Commonwealth System Of Higher Education Methods and materials for expanding tumor infiltrating gamma-delta t cells
JP2025506506A (ja) 2022-02-16 2025-03-11 プリオセラ エスエーエス Ｓ１ｐ受容体モジュレーターと組み合わせたｃａｒ細胞を用いた処置方法
CN114645022B (zh) * 2022-05-13 2022-09-02 首都医科大学宣武医院 靶向CD5的CAR-γ δ T细胞及其制备方法与应用
WO2023235511A1 (en) * 2022-06-01 2023-12-07 Sens Research Foundation Targeted elimination of senescent cells by gamma-delta t cells
CN116813794B (zh) * 2023-02-27 2024-07-12 武汉波睿达生物科技有限公司 共表达spi1的嵌合抗原受体及其应用
EP4458412A1 (en) 2023-05-05 2024-11-06 University College Cardiff Consultants, Ltd. Novel phosphoantigen prodrug compound and use thereof
CN120554516B (zh) * 2025-07-30 2025-10-24 杭州华大生命科学研究院 抗cd45抗体及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360046A1 (en) 1999-01-28 2000-08-03 Lawrence S. Lamb, Jr. In vitro activated gamma delta lymphocytes
AU4816201A (en) 2000-04-03 2001-10-15 Hemosol Inc Production of tcr gamma delta t cells
ES2302106T3 (es) 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
WO2006006720A1 (ja) 2004-07-13 2006-01-19 Medinet., Co.Ltd γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤
DK1778836T3 (da) 2004-08-19 2010-11-22 Univ Cardiff Fremstilling af antigenpræsenterende humane gammadelta-T-celler og anvendelse ved immunterapi
KR101419711B1 (ko) 2005-09-08 2014-07-17 가부시키가이샤 메디넷 항원제시세포의 활성화 처리방법
WO2008152822A1 (ja) 2007-06-15 2008-12-18 Medinet Co., Ltd. 医薬
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
WO2014124143A1 (en) 2013-02-06 2014-08-14 Anthrogenesis Corporation Modified t lymphocytes having improved specificity
KR102238226B1 (ko) 2013-05-14 2021-04-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용
EP3925618A1 (en) 2013-07-29 2021-12-22 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
CA2926859A1 (en) 2013-10-25 2015-04-30 Board Of Regents, The University Of Texas System Polyclonal gamma delta t cells for immunotherapy
WO2015066262A1 (en) 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
WO2015075468A1 (en) 2013-11-21 2015-05-28 Ucl Business Plc Cell
KR102375998B1 (ko) 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 및 제조방법
WO2015142675A2 (en) * 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
KR20160145802A (ko) 2014-04-23 2016-12-20 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
JP2017524031A (ja) 2014-07-09 2017-08-24 ティーシー バイオファーム リミテッド ガンマデルタｔ細胞およびその使用
US11135245B2 (en) 2014-11-17 2021-10-05 Adicet Bio, Inc. Engineered γδ T-cells
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
CN105158466B (zh) * 2015-05-05 2017-12-22 中国科学院广州生物医药与健康研究院 一种检测抗cd19的嵌合抗原受体t细胞对白血病细胞抑制作用的方法

Also Published As

Publication number Publication date
WO2016166544A1 (en) 2016-10-20
ZA201706922B (en) 2023-06-28
EP3283620A1 (en) 2018-02-21
CN107810267A (zh) 2018-03-16
BR112017022249A2 (pt) 2018-07-10
IL255011B (en) 2021-09-30
CA2982523A1 (en) 2016-10-20
AU2016250211B2 (en) 2022-03-03
US20180125889A1 (en) 2018-05-10
US10881688B2 (en) 2021-01-05
KR20180012754A (ko) 2018-02-06
AU2022203664A1 (en) 2022-06-16
CN107810267B (zh) 2022-03-04
JP6995624B2 (ja) 2022-02-21
SG11201708401WA (en) 2017-11-29
JP2022046549A (ja) 2022-03-23
AU2016250211A1 (en) 2017-11-02
EP3283620B1 (en) 2024-08-28
ES2993441T3 (en) 2024-12-30
JP2018512161A (ja) 2018-05-17
IL255011A0 (en) 2017-12-31
CN114717194A (zh) 2022-07-08
HK1250741A1 (en) 2019-01-11
US20210252055A1 (en) 2021-08-19
EA201792041A1 (ru) 2018-04-30

Similar Documents

Publication Publication Date Title
IL255011B (en) Modified gamma delta cells and their uses
IL249970A0 (en) Gamma delta T cells and their uses
SG10201912825XA (en) Genetically modified cells and uses thereof
IL254734A0 (en) Modified t cells and methods for their preparation and use
SG10201912576PA (en) Natural killer cells and ilc3 cells and uses thereof
SG11201706029VA (en) Anti-senescence compounds and uses thereof
GB201713078D0 (en) T Cell Modification
GB201616238D0 (en) Modified T cells
IL297057B2 (en) Conjunctions and their uses
ZA201705456B (en) Benzoxaborole compounds and uses thereof
IL273247A (en) New cell row and its uses
GB201504763D0 (en) Compounds and uses
IL254241A0 (en) Etv2 and its uses
GB201517786D0 (en) Methods and materials
IL254287A0 (en) Cyclic galanin analogs and uses thereof
IL253459A0 (en) Isoergoline compounds and their uses
PL3387139T3 (pl) Beta-glukozydaza i jej zastosowania
IL275211A (en) Fast and flexible segment chains - division
GB201718875D0 (en) Autophagy-inhibiting compounds and uses thereof
GB201401373D0 (en) Compositions for cells lysis and uses thereof
GB201415379D0 (en) Gamma T cells and uses thereof
GB201412175D0 (en) Gamma T cells and uses thereof
GB201616232D0 (en) Novel cell line and uses thereof
HK1261250A1 (en) Modified immune cells and uses thereof
AU2015904933A0 (en) Genetically modified cells and uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)